K. A. Chemodakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
K. A. Chemodakova has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Boris V. Martynov
Kirov Military Medical Academy
3 shared publications - Dmitrij Vladimirovich Svistov
Kirov Military Medical Academy
3 shared publications - Emma Yu. Klimenkova
Medical Military Academy
2 shared publications - Igor’ Vyacheslavovich Litvinenko
S.M. Kirov Military Medical Academy
2 shared publications - Mikhail Yu. Prokudin
Medical Military Academy
2 shared publications - Olga A. Klitsenko
Mechnikov North-West State Medical University
2 shared publications
Latest Publications
- 22 April 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 4,p. 391-402
The role of surgical treatment of recurrent glioblastomas
Introduction. With standard treatment of glioblastoma, the vast majority of cases result in relapse of the disease, for which there is no consensus on the effectiveness of repeat resection. The lack of Level 1 evidence on the efficacy of surgical removal of recurrent glioblastomas (GB) indicates that the problem has not been resolved and stimulates interest in finding ways to combat this disease. Purpose. To study the effect of surgical treatment of a recurrent tumor on the overall life expectancy and post-relapse survival time of patients with glioblastomas. Materials and methods. The analysis was performed on data from 116 patients: 43 (37.1 %) women and 73 (62.9 %) men. The mean age at the time of diagnosis (primary surgery) was 52±12 full years. Surgical interventions were performed between 1999 and 2017. The study group included 50 patients who underwent GB resection. The control group consisted of 66 patients who were not operated on for GB. To achieve group homogeneity for all studied variables, the pseudo-randomization method was used. Statistical analysis was performed using the program SPSS Statistics 26.0. Results. The median overall life expectancy after GB resection was 23.6 [95 % CI=18.1–29.1] months, in the control group — 21.0 [95 % CI=12.8–29.2] months. The fatal outcome for the patients in the study group was simultaneously influenced by two characteristics: the duration of the relapse-free period (p=0.003) and the volume of the recurrent tumor (p=0.050). For the patients in the control group, only the duration of the relapse-free period (p <0.001) was impactful. The median post-relapse survival time was higher in those patients who underwent resection of 95 % or more of the GB volume than in those without surgery: 10.33 months [95 % CI 9.67 — NA months] and 6.33 months [95 % CI 5.07–11.2 months] (p<0.05), respectively. The 2‑year survival rate in the group after resection of 95 % or more of the GB volume is more than twice as high as in the non-operated group: 38.5 % and 13.7 %, respectively. Conclusions. Maximum reduction in GB volume appears to be advisable, especially in patients with a long relapse- free period when the formation is localized in the subdominant hemisphere of the brain, without spreading to the corpus callosum. Microsurgical removal of recurrent glioblastomas is an effective method of treating patients in comparison with conservative therapy.
- 22 April 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 4,p. 391-402
The role of surgical treatment of recurrent glioblastomas
Introduction. With standard treatment of glioblastoma, the vast majority of cases result in relapse of the disease, for which there is no consensus on the effectiveness of repeat resection. The lack of Level 1 evidence on the efficacy of surgical removal of recurrent glioblastomas (GB) indicates that the problem has not been resolved and stimulates interest in finding ways to combat this disease. Purpose. To study the effect of surgical treatment of a recurrent tumor on the overall life expectancy and post-relapse survival time of patients with glioblastomas. Materials and methods. The analysis was performed on data from 116 patients: 43 (37.1 %) women and 73 (62.9 %) men. The mean age at the time of diagnosis (primary surgery) was 52±12 full years. Surgical interventions were performed between 1999 and 2017. The study group included 50 patients who underwent GB resection. The control group consisted of 66 patients who were not operated on for GB. To achieve group homogeneity for all studied variables, the pseudo-randomization method was used. Statistical analysis was performed using the program SPSS Statistics 26.0. Results. The median overall life expectancy after GB resection was 23.6 [95 % CI=18.1–29.1] months, in the control group — 21.0 [95 % CI=12.8–29.2] months. The fatal outcome for the patients in the study group was simultaneously influenced by two characteristics: the duration of the relapse-free period (p=0.003) and the volume of the recurrent tumor (p=0.050). For the patients in the control group, only the duration of the relapse-free period (p <0.001) was impactful. The median post-relapse survival time was higher in those patients who underwent resection of 95 % or more of the GB volume than in those without surgery: 10.33 months [95 % CI 9.67 — NA months] and 6.33 months [95 % CI 5.07–11.2 months] (p<0.05), respectively. The 2‑year survival rate in the group after resection of 95 % or more of the GB volume is more than twice as high as in the non-operated group: 38.5 % and 13.7 %, respectively. Conclusions. Maximum reduction in GB volume appears to be advisable, especially in patients with a long relapse- free period when the formation is localized in the subdominant hemisphere of the brain, without spreading to the corpus callosum. Microsurgical removal of recurrent glioblastomas is an effective method of treating patients in comparison with conservative therapy.
- 22 February 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 2,p. 213-224
Quality of life indicators in patients with diffuse brain gliomas
The incidence of primary brain tumors is increasing worldwide. When assessing the treatment delivered to patients with brain gliomas, their quality of life (QOL) is an essential criterion for consideration. It is necessary to search for and specify the factors, which determine the QOL changes in patients with brain tumors. The QOL indicators for patients with brain gliomas were assessed in terms of the following factors: clinical (presence of epileptic seizures, seizures type and frequency, antiepileptic drug treatment, presence of speech disorders and pareses), demographic (sex), age of diagnosis, social (level of education, employment, marital status), molecular-genetic (presence of IDH1/2 mutation, 1p/19q codeletion), and morphological (malignancy degree, tumor histological characteristics). The QOL of 48 patients with diffuse brain gliomas was tested according to the objectives of the study. The QOLIE-31 questionnaire (version 1.0) indicates that diffuse glioma patients with epilepsy have statistically significant decrease in such QOL spheres as seizures worry (p<0.0001), cognitive functioning (p=0.0043), antiepileptic drug effect (p=0.0002), social functioning (p=0.0029), as well as in the total score (p=0.0053). In addition, such factors as age, gender, tumor malignancy degree, and its histological type have a statistically significant effect on the QOL of patients with diffuse brain gliomas before surgery. Thus, the treatment of patients with diffuse brain gliomas requires a thorough study and a multidisciplinary approach, including such specialists as a neurologist, oncologist, chemotherapist, radiologist, neuropsychologist, and psychiatrist, in addition to a neurosurgeon.
- 22 February 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 2,p. 213-224
Quality of life indicators in patients with diffuse brain gliomas
The incidence of primary brain tumors is increasing worldwide. When assessing the treatment delivered to patients with brain gliomas, their quality of life (QOL) is an essential criterion for consideration. It is necessary to search for and specify the factors, which determine the QOL changes in patients with brain tumors. The QOL indicators for patients with brain gliomas were assessed in terms of the following factors: clinical (presence of epileptic seizures, seizures type and frequency, antiepileptic drug treatment, presence of speech disorders and pareses), demographic (sex), age of diagnosis, social (level of education, employment, marital status), molecular-genetic (presence of IDH1/2 mutation, 1p/19q codeletion), and morphological (malignancy degree, tumor histological characteristics). The QOL of 48 patients with diffuse brain gliomas was tested according to the objectives of the study. The QOLIE-31 questionnaire (version 1.0) indicates that diffuse glioma patients with epilepsy have statistically significant decrease in such QOL spheres as seizures worry (p<0.0001), cognitive functioning (p=0.0043), antiepileptic drug effect (p=0.0002), social functioning (p=0.0029), as well as in the total score (p=0.0053). In addition, such factors as age, gender, tumor malignancy degree, and its histological type have a statistically significant effect on the QOL of patients with diffuse brain gliomas before surgery. Thus, the treatment of patients with diffuse brain gliomas requires a thorough study and a multidisciplinary approach, including such specialists as a neurologist, oncologist, chemotherapist, radiologist, neuropsychologist, and psychiatrist, in addition to a neurosurgeon.
- Open Access
- 27 July 2022
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 14 (2) , 204-213
The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
- 27 July 2022
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 14 (2) , 204-213
Open AccessThe role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
- Open Access
- 26 October 2021
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 23 (3) , 59-68
Features of intraoperative neuromonitoring of the supplementary motor area of the brain. Literature review and case report
Introduction. Supplementary motor area (SMA) syndrome is a symptom complex resulting from damage to the premotor cortex and it’s subcortical projection. There is no generally accepted protocol for functional mapping of SMA during neurosurgical intervention in this area.The objective of the publication is to present a review of the literature and clinical cases from practice that describes the treatment of two patients with glioblastomas in the posterior regions of the superior frontal gyrus with IOM. Given the localization of the tumor in the dominant hemisphere, one operation was performed with awakening, the other according to the protocol of total intravenous anesthesia with mapping of only motor representative areas.Clinical cases. In both cases, during intraoperative direct electrical stimulation of the cortex subjected to resection, evoked motor responses were not recorded. The modalities used made it possible to continuously evaluate the viability of the cortico‑spinal tract. During the surgery with awakening, episodes of an instantaneous termination of the initia‑ tion of speech and counter directional movements in the arm were recorded – in the subcortical projection of the SMA at a current strength of 1–2 mA. Both patients in the early postoperative period showed the development of a gross transient neurological deficit in the form of hemiparesis and sensorimotor aphasia, which was a manifestation of pos‑ tresection SMA syndrome. During the follow‑up (control) examination 6–7 months after the operation, the following was observed in the clinical picture: mild hemiparesis up to 4–5 points, impaired bimanual coordination; difficulty the ini‑ tiation of speech spontaneous speech.Conclusion. When mapping the cortex and subcortical structures, the localization of SMA can be assumed in the event of a negative motor response of the cerebral cortex using the protocol of low‑frequency 1 Hz stimulation under EcoG control. Standardization of the SMA mapping protocol would be useful in clinical practice for determining the bounda
- 26 October 2021
- Published by "MedINK" Publishing House in Russian journal of neurosurgery
- Vol. 23 (3) , 59-68
Open AccessFeatures of intraoperative neuromonitoring of the supplementary motor area of the brain. Literature review and case report
Introduction. Supplementary motor area (SMA) syndrome is a symptom complex resulting from damage to the premotor cortex and it’s subcortical projection. There is no generally accepted protocol for functional mapping of SMA during neurosurgical intervention in this area.The objective of the publication is to present a review of the literature and clinical cases from practice that describes the treatment of two patients with glioblastomas in the posterior regions of the superior frontal gyrus with IOM. Given the localization of the tumor in the dominant hemisphere, one operation was performed with awakening, the other according to the protocol of total intravenous anesthesia with mapping of only motor representative areas.Clinical cases. In both cases, during intraoperative direct electrical stimulation of the cortex subjected to resection, evoked motor responses were not recorded. The modalities used made it possible to continuously evaluate the viability of the cortico‑spinal tract. During the surgery with awakening, episodes of an instantaneous termination of the initia‑ tion of speech and counter directional movements in the arm were recorded – in the subcortical projection of the SMA at a current strength of 1–2 mA. Both patients in the early postoperative period showed the development of a gross transient neurological deficit in the form of hemiparesis and sensorimotor aphasia, which was a manifestation of pos‑ tresection SMA syndrome. During the follow‑up (control) examination 6–7 months after the operation, the following was observed in the clinical picture: mild hemiparesis up to 4–5 points, impaired bimanual coordination; difficulty the ini‑ tiation of speech spontaneous speech.Conclusion. When mapping the cortex and subcortical structures, the localization of SMA can be assumed in the event of a negative motor response of the cerebral cortex using the protocol of low‑frequency 1 Hz stimulation under EcoG control. Standardization of the SMA mapping protocol would be useful in clinical practice for determining the bounda